A Phase 1 Study of the Antibody-Radionuclide Conjugate SLR-108 for Positron Emission Tomography Imaging in Subjects With Metastatic Solid Tumors
Solve Therapeutics
Summary
This is a Phase 1 study evaluating the feasibility of using SLR-108 for positron-emission tomography (PET) imaging of metastatic solid tumors.
Description
This study will assess the safety, pharmacokinetics, biodistribution, radiation dosimetry, and image quality of a single IV injection of the diagnostic radiopharmaceutical SLR-108, evaluating a range of antibody protein dose levels and radioactivity dose levels in subjects with metastatic solid tumors. PET imaging will be performed following administration of SLR-108.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria * Men or women (as appropriate for cancer type) of age ≥18 years. * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. * Histologically or cytologically confirmed diagnosis of solid tumor as documented in medical records. * Based on the most recent tumor assessment, presence of metastatic disease that has progressed during or following previous treatment. * Presence of radiographically measurable disease (defined as the presence of ≥1 non-osseous tumor lesion that measures ≥10 mm in longest dimension \[≥15 mm in shortest dimension for lymph nodes\]…
Interventions
- DrugSLR-108
SLR-108 is an antibody-radionuclide conjugate.
- DrugSLX-1411
SLX-1411 is a non-radiolabeled antibody.
Location
- Hoag Memorial Hospital PresbyterianNewport Beach, California